{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:03:58Z","timestamp":1789625038663,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence linking tamoxifen to hypertriglyceridemia (HTG) is mainly derived from case reports. This study aimed to evaluate clinical characteristics and provide evidence to improve identification and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Databases including China National Knowledge Infrastructure (CNKI), Wanfang, VIP, Web of Science, PubMed, Embase, and Elsevier were searched up to 25 February 2026. Case reports and case series on tamoxifen-induced hypertriglyceridemia (HTG) were collected and descriptively analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 49 patients (2 males, 47 females) were included, with a median age of 49 years (range 34\u201374). Acute pancreatitis (AP) occurred in 31 patients (63.3%). Median triglyceride (TG) levels increased from 274\u00a0mg\/dL before treatment to 2,534\u00a0mg\/dL after tamoxifen initiation. Median time to HTG onset was 6 months, and to AP symptoms 9 months. Compared with the non-AP group, the AP group was younger (median 47 vs. 50.5 years, (p = 0.005)), had a higher prevalence of hypertension (25.6% vs. 0%, (p = 0.029)), and had higher post-treatment TG levels (3,358 vs. 1,566\u00a0mg\/dL, (p = 0.051)). Logistic regression identified younger age as an independent risk factor for AP, with risk decreasing by approximately 15% per year of age (OR 0.849, 95% CI 0.750\u20130.961, (p = 0.01)). In three patients who underwent rechallenge, HTG recurred significantly faster (median 17.5 days). Tamoxifen was discontinued in most patients (39\/49), and 81.6% received lipid-lowering therapy. TG normalization time was shorter in the AP group (median 11.5 vs. 60 days, (p = 0.003)). Forty-six patients improved. One died of liver failure, one left the hospital voluntarily due to septic shock, and one had unreported outcome. Causality was judged \u201cprobable\u201d in 85.7% (Naranjo scale).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tamoxifen-induced HTG is a significant and frequent risk factor for AP, which can be severe. Younger age is inversely correlated with AP risk. Close lipid monitoring, especially during the first year of treatment and in patients with metabolic disorders, is crucial. Prompt drug discontinuation, aggressive lipid-lowering therapy, and supportive care are key to management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1838781","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:34:03Z","timestamp":1789623243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics, management, and outcome of tamoxifen-induced hyperlipidemia: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Juan","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingHui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangdong Provincial Second Hospital of Traditional Chinese Medicine (Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine)","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZuYi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongliang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.36347\/sjmcr.2020.v08i08.012","article-title":"AP secondary to the drug tamoxifen: about a new clinical case","volume":"8","author":"Aboutarik","year":"2020","journal-title":"Sch. J. Med. Case Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00044011-200626050-00007","article-title":"Tamoxifen-induced severe hypertriglyceridaemia and AP","volume":"26","author":"Alagozlu","year":"2006","journal-title":"Clin. Drug Investig."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S752","DOI":"10.14309\/01.ajg.0000780280.13126.b8","article-title":"Tamoxifen-induced HTG leading to AP","volume":"116","author":"Amin","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/joc.2002.14.3.309","article-title":"Asymptomatic AP due to tamoxifen-induced severe HTG in a patient with diabetes mellitus and breast cancer","volume":"14","author":"Artac","year":"2002","journal-title":"J. Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classiffcation of AP-2012: revision of the Atlanta classiffcation and deffnitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.55519\/JAMC-04-7330","article-title":"Effect of tamoxifen on plasma lipid profile in patients of breast cancer","volume":"35","author":"Bhunisha","year":"2023","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"B7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J. Gen. Intern Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/1097-0142(19860601)57:11<2123::aid-cncr2820571106>3.0.co;2-2","article-title":"Severe lipemia induced by tamoxifen","volume":"57","author":"Brun","year":"1986","journal-title":"Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.12092\/j.issn.1009-2501.2018.06.020","article-title":"Research progress on the mechanism of tamoxifen-induced non-alcoholic fatty liver disease","volume":"23","author":"Chen","year":"2018","journal-title":"Chin. J. Clin. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1210\/js.2019-00096","article-title":"Cardiometabolic effects of endocrine treatment of estrogen receptor-positive early breast cancer","volume":"3","author":"Cheung","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/s0936-6555(98)80019-8","article-title":"Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use","volume":"10","author":"Colls","year":"1998","journal-title":"Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5114\/pm.2014.41089","article-title":"Tamoxifen-induced AP - a case report","volume":"13","author":"Czy\u017cykowski","year":"2014","journal-title":"Prz. Menopauzalny"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1023\/a:1008309613082","article-title":"Tamoxifen-induced severe HTG and pancreatitis","volume":"11","author":"Elisaf","year":"2000","journal-title":"Ann. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1054\/brst.1999.0129","article-title":"Re: the influence of tamoxifen on serum triglycerides","volume":"9","author":"Elisaf","year":"2000","journal-title":"Breast"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MPA.0000000000001190","article-title":"HTG-associated drug-induced AP","volume":"48","author":"Elkhouly","year":"2019","journal-title":"Pancreas"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/10781552221093969","article-title":"AP secondary to tamoxifen-associated HTG:a clinical update","volume":"29","author":"Goraya","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"AEP326","DOI":"10.1530\/endoabs.73.AEP326","article-title":"A case of HTG after the use of tamoxifen","volume":"73","author":"Gunay","year":"2021","journal-title":"Endocr. Abstr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1507\/endocrj.44.745","article-title":"Severe HTG caused by tamoxifen-treatment after breast cancer surgery","volume":"44","author":"Hozumi","year":"1997","journal-title":"Endocr. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1210\/jcem.83.5.4753","article-title":"Effect of tamoxifen on serum lipid metabolism","volume":"83","author":"Hozumi","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.pan.2025.04.020","article-title":"International association of pancreatology revised guidelines on AP 2025","volume":"25","year":"2025","journal-title":"Pancreatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12902-021-00780-z","article-title":"A case of tamoxifen-induced HTG monitoring the changes in lipoprotein fractions over time","volume":"21","author":"Isobe","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15279\/kpba.2019.24.3.111","article-title":"HTG-induced severe necrotizing pancreatitis following low dose tamoxifen administration","volume":"24","author":"Jang","year":"2019","journal-title":"Kor. J. Pancreas Biliary Tract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/s0300-2977(99)00057-1","article-title":"Tamoxifen and HTG","volume":"55","author":"Jonkers","year":"1999","journal-title":"Neth. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1530\/ERC-14-0092","article-title":"Tamoxifen as the first targeted long-term adjuvant therapy for breast cance","volume":"21","author":"Jordan","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199707243370417","article-title":"Delayed severe HTG from tamoxifen","volume":"337","author":"Kanel","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"XD05","DOI":"10.7860\/jcdr\/2017\/27440.10467","article-title":"Tamoxifen induced pancreatitis:an unusual complication of commonly used drug","volume":"11","author":"Kataria","year":"2017","journal-title":"J. Clin. Diagn Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.11604\/pamj.2012.13.68.1581","article-title":"Hypertriglyc\u00e9rid\u00e9mie majeure sous tamoxif\u00e8ne","volume":"13","author":"Khabbal","year":"2012","journal-title":"Pan Afr. Med. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3978\/j.issn.1000-9604.2014.05.01","article-title":"Severe AP due to tamoxifen induced HTG with diabetes mellitus","volume":"26","author":"Kim","year":"2014","journal-title":"Chin. J. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S801","DOI":"10.14309\/00000434-201810001-01395","article-title":"Tamoxifen-induced HTG-induced pancreatitis: a rare side effect: 1395","volume":"113","author":"Kochar","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"A1919","DOI":"10.1164\/ajrccm-conference.2016.193.1_MeetingAbstracts.A1919","article-title":"Severe AP in a patient recently started on tamoxifen","volume":"193","author":"Li","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3760\/cma.j.issn.1674-1935.2018.06.010","article-title":"A case of AP induced by tamoxifen-associated hyperlipidemia","volume":"30","author":"Li","year":"2018","journal-title":"Chin. J. Pancratol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1252","DOI":"10.14309\/01.ajg.0000863768.64107.40","article-title":"Tamoxifen-induced HTG causing AP","volume":"117","author":"Liljenquist","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1023\/b:ddas.0000034561.37401.f2","article-title":"Tamoxifen-induced severe AP: a case report","volume":"49","author":"Lin","year":"2004","journal-title":"Dig. Dis. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.14053\/j.cnki.pper.202012015","article-title":"AP caused by tamoxifen:case report and literature review","volume":"23","author":"Lin","year":"2020","journal-title":"Pract. Pharm. Clin. Remedies"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1038\/s41467-025-57615-x","article-title":"Endocrine-exocrine miR-503-322 drives aging-associated pancreatitis via targeting MKNK1 in acinar cells","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.14109\/j.cnki.xyylc.2022.07.13","article-title":"A case of AP caused by HTG induced by toremifene","volume":"41","author":"Lv","year":"2022","journal-title":"Chin. J. New Drugs Clin. Rem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3892\/or.4.3.625","article-title":"Tamoxifen-induced hypertriglyceridaemia","volume":"4","author":"Mikhailidis","year":"1997","journal-title":"Oncol. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e53779","DOI":"10.7759\/cureus.53779","article-title":"Tamoxifen- and triptorelin-induced major HTG: a case report","volume":"16","author":"Moussaoui","year":"2024","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/j.1552-4604.1992.tb04635.x","article-title":"Advance in the diagnosis of adverse drug reactions","volume":"32","author":"Naranjo","year":"1992","journal-title":"J. Clin. Pharmacol."},{"key":"B41","unstructured":"NCCN clinical practice guidelines in oncology:breast cancer (version 1.2026)"},{"key":"B42","unstructured":"NCCN clinical practice guidelines in oncology:uterine neoplasms (version 1.2026)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/bjs.1800740714","article-title":"Fatal hyperlipaemia in a case of metastatic breast cancer treated by tamoxifen","volume":"74","author":"Noguchi","year":"1987","journal-title":"Br. J. Surg."},{"key":"B44","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting. Mild-to-moderate HTG and risk of AP","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"B46","first-page":"382","article-title":"Severe AP due to tamoxifen induced HTG with positive rechallenge","volume":"11","author":"Sakhri","year":"2010","journal-title":"J. Pancreas"},{"key":"B47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.4321\/s0212-71992005000600012","article-title":"Hiperlipidemia inducida por tamoxifeno","volume":"25","author":"S\u00e1nchez","year":"2005","journal-title":"An. Med. Interna"},{"key":"B48","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1524-4741.2009.00809.x","article-title":"Tamoxifen induced severe HTG in a male patient with breast carcinoma","volume":"15","author":"Santeufemia","year":"2009","journal-title":"Breast J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"A1945","DOI":"10.1164\/ajrccm-conference.2016.193.1_MeetingAbstracts.A1945","article-title":"Tamoxifen induced HTG: an underrecognized and rare cause of pancreatitis","volume":"193","author":"Sedhom","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00280-017-3491-6","article-title":"Serum lipid and bone metabolism effects of toremifene vs. letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study","volume":"81","author":"Shien","year":"2018","journal-title":"Cancer Chemother. Pharm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"B52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/0976-500x.179365","article-title":"Tamoxifen induced HTG causing AP","volume":"7","author":"Singh","year":"2016","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B53","first-page":"1","article-title":"AP secondary to tamoxifen-induced HTG","volume":"26","author":"Sprague","year":"2022","journal-title":"Proc. UCLA Health"},{"key":"B54","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3143\/geriatrics.35.858","article-title":"Severe HTG induced by tamoxifen","volume":"35","author":"Taira","year":"1998","journal-title":"Jpn. J. Geriatrics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/crj.0000000000000025","article-title":"AP caused by tamoxifen-induced severe HTG after 4 years of tamoxifen use","volume":"6","author":"Tey","year":"2019","journal-title":"ACG Case Rep. J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5505\/tjoncol.2011.386","article-title":"Tamoxifen-induced severe AP after a short-term therapy:a case report","volume":"26","author":"\u00dcskent","year":"2011","journal-title":"Turk Onkol. Derg."},{"key":"B57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur. J. Intern Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"bcr2016214837","DOI":"10.1136\/bcr-2016-214837","article-title":"Tamoxifen precipitation of familial hypertriglyceridaemia: a rare cause of AP","volume":"2016","author":"Wadood","year":"2016","journal-title":"BMJ Case Rep."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1758835920925991","DOI":"10.1177\/1758835920925991","article-title":"Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal armatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study","volume":"12","author":"Wang","year":"2020","journal-title":"Ther. Ady Med. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.pharmthera.2013.05.005","article-title":"Toxicity and adverse effects of tamoxifen and other anti-estrogen drugs","volume":"139","author":"Yang","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/tbj.13279","article-title":"Severe AP due to tamoxifen-induced HTG","volume":"25","author":"Yoneyama","year":"2019","journal-title":"Breast J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1103637","DOI":"10.3389\/fonc.2023.1103637","article-title":"Severe hyperlipidemia pancreatitis induced by taking tamoxifen after breast cancer surgery\u2014case report","volume":"13","author":"Zhai","year":"2023","journal-title":"Front. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.12677\/acm.2024.1472159","article-title":"Secondary HTG pancreatitis associated with tamoxifen:a case report and literature review","volume":"14","author":"Zhang","year":"2024","journal-title":"Adv. Clin. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ijc.33919","article-title":"Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: a propensity-score matched cohort study","volume":"150","author":"Zhou","year":"2022","journal-title":"Int. J. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1838781\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:34:11Z","timestamp":1789623251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1838781\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":64,"alternative-id":["10.3389\/fphar.2026.1838781"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1838781","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1838781"}}